RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis

Hongli Yu(Liuzhou General Hospital), Qiang Zhu(Shandong University), Yang Yao(University of Science and Technology of China), Yuping Bai(Chengdu University of Traditional Chinese Medicine), Xiaoyu Xie(Nanjing University of Science and Technology), Yuemin Feng(Shandong Provincial Hospital)
BMJ Open
June 1, 2022
Cited by 42


Related Papers